Table 1 The compounds selected from the Drugbank database based on their binding affinity for the four vital targets in Covid-19.

From: Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach

3CLpro PLpro RdRp Spike
Approved
Olaparib (\(-\) 9.2) Tadalafil (\(-\) 9.2) Lumacaftor (\(-\) 9.9) Dexamethasone metasulfobenzoate (\(-\) 10.4)
Baloxavir marboxil (\(-\) 8.9) Metocurine(\(-\) 9.0) Ergotamine (\(-\) 9.4) Nilotinib (\(-\) 9.9)
Entrectinib, (− 8.7) Lorlatinib (\(-\) 9.0) Natamycin(\(-\) 9.4) Sonidegib (\(-\) 9.8)
Dexamethasone metasulfobenzoate (\(-\) 8.7) Lumacaftor (\(-\) 8.9) Dihydroergotamine (\(-\) 9.3) Enasidenib (\(-\) 9.8)
Tadalafil (\(-\) 8.7) Natamycin (\(-\) 8.8) Imatinib (\(-\) 9.3) Regorafenib, Lifitegrast, Capmatinib (\(-\) 9.7)
Investigational
LY-2090314 (\(-\) 10.3) Zoliflodacin (\(-\) 9.8) Phthalocyanine (\(-\) 10.6) Lifirafenib (\(-\) 10.7)
10-hydroxy camptothecin (\(-\) 9.3) JE-2147 (\(-\) 9.7) RU85053 (\(-\) 9.9) Resiniferatoxin (\(-\) 10.6)
Tivantinib (\(-\) 9.0) Phthalocyanine (\(-\) 9.6) Laniquidar (\(-\) 9.9) JTK-853 (\(-\) 10.6)
Lurtotecan (\(-\) 9.0) Quarfloxin (\(-\) 9.5) CD564 (\(-\) 9.8) Tegobuvir (\(-\) 10.5)
Zk-806450 (\(-\) 8.9) CP-609754 (\(-\) 9.5) Golvatinib (\(-\) 9.8) PCO-371 (\(-\) 10.5)
  1. The binding affinities are given in kcal/mol.